| Trial ID: | L3170 |
| Source ID: | NCT06532682
|
| Associated Drug: |
Dapagliflozin
|
| Title: |
Efficacy of Dapagliflozin in Early Diabetic Nephropathy in Type 1 Diabetes
|
| Acronym: |
|
| Status: |
ACTIVE_NOT_RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetic Kidney Disease|Type 1 Diabetes
|
| Interventions: |
DRUG: dapagliflozin|DRUG: ACE inhibitor
|
| Outcome Measures: |
Primary: Urinary albumin-to-creatinine ratio, Average change from baseline to 24 weeks after treatment, From baseline to 24 weeks|estimated Glomerular Filtration Rate, Average change from baseline to 24 weeks after treatment, From baseline to 24 weeks | Secondary: 24-hour urine biochemical quantification, Average change from baseline to 24 weeks after treatment, From baseline to 24 weeks|HbA1c, Change from baseline to 24 weeks after treatment, From baseline to 24 weeks|Weight, Change from baseline to 24 weeks after treatment, From baseline to 24 weeks|Time in Range, Evaluate blood glucose control through continuous glucose monitoring, From baseline to 24 weeks|Daily insulin dose, Change from baseline to 24 weeks after treatment, From baseline to 24 weeks
|
| Sponsor/Collaborators: |
Sponsor: The First Affiliated Hospital with Nanjing Medical University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
54
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2024-07-01
|
| Completion Date: |
2026-10-01
|
| Results First Posted: |
|
| Last Update Posted: |
2024-08-01
|
| Locations: |
Nanjing Medical University First Affiliated Hospital, Nanjing, Jiangsu, 210000, China
|
| URL: |
https://clinicaltrials.gov/show/NCT06532682
|
